ESG Viewpoint: updates

Subscribe to our insights

What are neonics?

Over the last 12 months, we requested dialogue with ten companies involved in the production of neonics, namely FMC Corp, Nufarm Ltd, K+S AG, Israel Chemicals Ltd, Monsanto Co, Yara International ASA, Mosaic Co, CF Industries Holdings Inc, Syngenta AG and BASF SE.

Of the ten companies we reached out to, all but four were responsive, though they offered varying degrees of openness when discussing the topic – and not all were willing to discuss their biodiversity risk management in depth.

We will continue to engage with those who failed to provide us with information on this issue to ensure that their biodiversity-related risks, including reputational risks, are managed with a transparent approach.

Risk Disclaimer

The value of investments and any income derived from them can go down as well as up as a result of market or currency movements and investors may not get back the original amount invested.

reo® is a registered trademark of BMO Asset Management (Holdings) PLC.

Case Study:

BASF

Since we believe that BASF would be affected by the EU’s ban, we prioritised it in our engagement plan. We spoke with the company to ask how they take considerations of bee health into account within their product development strategy. With a 250-strong team working on product and chemical safety, the company has well-developed procedures, but we wanted to understand how this is helping them to navigate the rapidly changing regulatory situation.

BASF informed us that, since 2019, bee protection is formalised in their R&D process. Bee experts conduct toxicology tests at an early stage of the product development cycle, and only products that won’t cause bee mortality will then be further developed. BASF has also been conducting farmer training to educate smallholders on the right ways to apply their products to avoid biodiversity harm, as well as post-sale product research to determine impacts on the ground.

We were impressed with the level of detail shared by the company, but this does not entirely mitigate the risks, particularly given the complexities of integrating the recently acquired Bayer assets. We encouraged the company to improve its reporting in this area.

Use our handy glossary to look up any technical jargon.

Related articles

Multi-Asset
Female office worker looking at a computer screen and making notes on a notepad
4 min watch
January 2022

Weekly review: Is the equity Bull market over?

US inflation hits 7%, the highest for 40 years and the Fed talks tough.
Uncategorised
Power station
2 min read
January 2022

Our 2022 engagement priorities to address climate change and biodiversity

COP26 served to further highlight the scale of the challenge in addressing climate change.
Global Equities
Robotic arm
7 min read

Losing your fragility – rise of the robots

Discover how COVID-19 is accelerating automation across a host of industries and where we’re finding investment opportunities.
View more